Norway· NO-ID_BAEB837E-F91B-4450-8426-E891D7D529E6
Ultomiris
A ravulizumab product containing ravulizumab, registered in Norway by Alexion Europe SAS (2). The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Ravulizumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AJ02 (ravulizumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Ravulizumab · ATC L04AJ02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Ravulizumab
- Manufacturer
- Alexion Europe SAS (2)
- Country
- Norway (NO)
- ATC code
- L04AJ02
- ATC class
- Ravulizumab
- Defined daily dose
- 70 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_BAEB837E-F91B-4450-8426-E891D7D529E6
- no_varenummer12129411NOK 240630.1
- gtin5391527744498
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for ravulizumab.
Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ravulizumab · interactions on record
2 records
Same medicine, other countries
Ravulizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumUltomiris 1100 mg/11 mlAlexion Europe
- CzechiaULTOMIRISAlexion Europe SAS, Levallois-Perret
- FinlandUltomirisAlexion Europe SAS
- SwedenUltomiris 1100 mg/11 ml Koncentrat till infusionsvätska, lösningAlexion Europe SAS
- IcelandULTOMIRISAlexion Europe SAS
- PolandUltomirisAlexion Europe SAS
- IrelandUltomiris 300 mg/3 mL concentrate for solution for infusionAlexion Europe S.A.S.
- United KingdomUltomiris 1,100mg/11ml concentrate for solution for infusion vialsAlexion Pharma UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Ultomiris
- Liechtenstein · Ultomiris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/80b0a240-1109-4afc-bea1-3cafe466ea2d GET /v1/drugs/80b0a240-1109-4afc-bea1-3cafe466ea2d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Ravulizumab",
"merkevare_id": "ID_BAEB837E-F91B-4450-8426-E891D7D529E6",
"name_form_strength": "Ultomiris kons til inf oppl 1100 mg/11 ml",
"prescription_group": "C"
}See everything about ravulizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.